DEAL EXPECTED TO BE ADJUSTED EBITDA MARGIN ACCRETIVE
CHEWY TO ACQUIRE SMARTEQUINE, EXPANDING LEADERSHIP IN THE EQUINE HEALTH CATEGORY
DEAL IS AN ALL-CASH DEAL
REAFFIRMS ITS Q3 FISCAL YEAR 2025 FINANCIAL GUIDANCE AS PROVIDED ON SEPTEMBER 10, 2025
Source text: [ID:]
Further company coverage: CHWY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.